Groundbreaking UK Bowel Cancer Trial Shows Zero Relapses After Three Years
A revolutionary British clinical trial for a specific type of bowel cancer has delivered astonishing results, with not a single patient experiencing a relapse nearly three years after receiving a new immunotherapy treatment. The findings, which have been hailed as a potential game-changer, could replace the need for debilitating chemotherapy for thousands of patients, offering them a much better quality of life and a greater chance of being cured.Background
Bowel cancer is the fourth most common cancer in the UK, with around 44,000 new cases diagnosed each year and nearly 17,700 deaths. For patients diagnosed with locally advanced stage 2 or 3 bowel cancer, the standard treatment pathway is gruelling. It typically involves surgery to remove the tumour, followed by a course of chemotherapy to kill any remaining cancer cells and reduce the risk of the disease returning. While this approach can be effective, chemotherapy comes with a host of severe side effects, including nausea, fatigue, hair loss, and an increased risk of infection. Furthermore, despite this aggressive treatment, around one in four patients will see their cancer return within three years.
In recent years, immunotherapy has emerged as a powerful new weapon in the fight against cancer. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy works by harnessing the power of the body's own immune system to recognise and destroy the tumour. This trial focused on a specific subset of bowel cancer patients whose tumours have a particular genetic makeup known as mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). This characteristic, found in about 10-15% of stage 2 or 3 patients, makes the cancer cells particularly susceptible to a type of immunotherapy called a checkpoint inhibitor.
The NEOPRISM-CRC trial, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), recruited 32 patients with this specific dMMR/MSI-H type of bowel cancer across five UK hospitals, including St. James's University Hospital in Leeds and The Christie NHS Foundation Trust in Manchester.
Key Developments
Instead of the standard care pathway, these patients were given a nine-week course of the immunotherapy drug pembrolizumab before their surgery. The aim was to see if the immunotherapy could shrink the tumour and clear away microscopic cancer cells before the operation, potentially removing the need for post-operative chemotherapy. The results, presented at the prestigious American Association for Cancer Research (AACR) Annual Meeting in April 2026, have exceeded all expectations.
As detailed in a UCL News release, after a median follow-up of 33 months, not a single one of the 32 patients has had their cancer return. This is a remarkable outcome, given the expected relapse rate of around 25% with standard care. Even more impressively, in 59% of the patients, there was no detectable cancer remaining at all when they underwent surgery after the immunotherapy course. One patient, 73-year-old Christopher Burston, who was diagnosed with stage 3 bowel cancer in February 2023, is now cancer-free more than three years later, having avoided chemotherapy entirely. Science publications like SciTechDaily have also highlighted the global significance of the findings.
Why It Matters
These results are a landmark moment in the treatment of bowel cancer. A 100% disease-free survival rate at this stage is almost unheard of in cancer trials. It suggests that for this specific group of patients, pre-operative immunotherapy could become the new standard of care, effectively curing a majority of them and saving all of them from the toxicity of chemotherapy. This represents a huge leap forward in personalised medicine, where treatment is tailored to the specific genetic profile of a patient's tumour.
The impact on patients' lives is immense. Avoiding chemotherapy means avoiding months of debilitating side effects, allowing people to maintain their quality of life, continue working, and recover from surgery much more quickly. It transforms a gruelling, life-altering treatment regimen into a much shorter, more tolerable, and ultimately more effective one. While this treatment currently only applies to the 10-15% of patients with dMMR/MSI-H tumours, that still represents around 2,000-3,000 people in the UK each year who could be spared chemotherapy and given a much higher chance of a cure. Comparatively, the standard 25% relapse rate under current treatment has been accepted as an unfortunate reality for decades; this trial suggests it need not be. The trial provides a powerful proof-of-concept that could inspire similar research in other cancer types.
Local Impact
In Northern Ireland, where bowel cancer rates are comparable to the rest of the UK, this breakthrough offers a new ray of hope for hundreds of patients and their families each year. The health service in Northern Ireland (HSC) will be under pressure to adopt this new treatment pathway as quickly as possible once it receives full regulatory approval. This will require investment in genomic testing to identify eligible patients and in the specialist oncology teams needed to deliver the immunotherapy. For patients in the region, it means the prospect of a more effective and less toxic treatment for their cancer is now on the horizon, a hugely significant development that will save lives and improve outcomes across the Belfast Health and Social Care Trust and beyond.
What's Next
The NEOPRISM-CRC trial is ongoing and will continue to follow the patients to confirm the long-term durability of the results. The findings will now be submitted to medical journals for peer review and to regulatory bodies like the MHRA in the UK and the EMA in Europe for licensing approval. Given the strength of the data, this process is expected to be fast-tracked. If approved, the next step will be for NHS England and the devolved health services to issue guidance and funding for the new treatment to be made available to all eligible patients across the UK, a process that could begin as early as 2027.
